GTP Scenario # 2 September 17,2005. Scenario # 2 Dr. Good received IND approval for CD8 depletion of allogeneic PBMC for a Phase I/II clinical trial.

Slides:



Advertisements
Similar presentations
Infection Control Program
Advertisements

Microbiological Validation
User requirements of a comprehensive ENVIRONMENTAL MONITORING software system Susan B. Cleary.
Health and Safety Executive Health and Safety Executive New Guidance What HSE expects John Healy HSE.
Facility Design and CGMP Considerations for Cell Therapy Products
Regulatory Challenges in the Cell Preparation Facility Adrian Gee Center for Cell & Gene Therapy Regulatory Challenges in the Cell Preparation Facility.
UC Davis Safety Services Monthly Safety Spotlight April 2010: Chemical and Laboratory Safety Safety Discussion Topics Critical Questions to Ask Laboratory.
1 The aim…. ‘to enable assessors to objectively assess a laboratory’s compliance with the new standards’
Good Manufacturing Practices Guilin, PRC Dr AJ van Zyl for Quality Assurance and Safety: Medicines Medicines Policy and Standards Health Technology and.
Prepared by Farid Khalaf.  Protect the worker.  Protect the sample being analyzed.  Protect the environment.
 Molecular Laboratory must have an ongoing Bio-safety SOP and also quality improvement program to monitor and evaluate objectively and systematically.
Lecture 8. Quality Assurance/Quality Control The Islamic University of Gaza- Environmental Engineering Department Environmental Measurements (EENV 4244)
1 Assessment: Audits. Assessment: Audits - Module 9 2 Learning Objectives At the end of this activity, you will be able to: Develop a process to prepare.
Quality Assurance/Quality Control Policy
CBER Irradiated Blood Components Jennifer Jones Consumer Safety Officer CBER, OBRR, DBA September 16, 2009.
Best Practices for Environmental Cleaning Module 6 - Audit.
Using EDC-Rave to Conduct Clinical Trials at Genentech
QC/QA Mary Malarkey Director, Division of Case Management Office of Compliance and Biologics Quality Center for Biologics Evaluation and Research March.
UNIT 3.04 Career Opportunities By PresenterMedia.comPresenterMedia.com.
Processing and Product Quality Issues Keith Wonnacott Ph.D. Office of Cellular, Tissue, and Gene Therapies E BC R Moving from Investigational to Licensed.
Pre-operative Assessment and Intra operative Nursing Role
Internal Auditing for Small Laboratories
Prof. Moustafa M. Mohamed Vice dean Faculty of Allied Medical Science Pharos University in Alexandria Development and Regulation of Medical Products (MEDR-101)
Waste Anesthetic Gases. The anesthetic gas and vapors that leak out into the surrounding room during medical and surgical procedures are considered waste.
PROFICIENCY TESTING Proficiency testing is a quality assurance test performed at regular intervals.
RAISING THE BAR Meeting CSA Guidelines And Preparing for Health Canada
7. EMERGENCY RESPONSE RYERSON UNIVERSITY.
3rd Dimension of Product Translation: Industrialization
Presented by Steven P. Feltman Food Safety and Quality Specialist.
Development and Regulation of Medical Products (MEDR-101)
Compounding Issues in Neuromodulation December 9, 2012 North American Neuromodulation Society 16 th Annual Scientific Meeting Wynn Hotel, Las Vegas Nevada.
GMP on blood/plasma collection establishments Group 2.
CBER HCT/P Contamination Prevention and Biologic Product Sterility Regulations Applicable to PBSCs Cell Therapy Liaison Meeting June 16, 2006 Ellen F.
Apheresis Blood Components
FDA Recommendations: Sampling Plans for Blood Establishments Lore Fields MT(ASCP)SBB Consumer Safety Officer OBRR/CBER/FDA October 19, 2012.
IN THE NAME OF GOD Quality Assurance and Blood Bank S. AMINI KAFI ABAD CLINICAL AND ANATOMICAL PATHOLOGIST IRANIAN BLOOD TRANSFUSION ORGANIZATION(IBTO)
Leukocyte-Reduced Blood Components Lore Fields MT(ASCP)SBB Consumer Safety Officer, DBA, OBRR, CBER September 16, 2009.
Overview of FDA's Regulatory Framework for PET Drugs
Sterile Products Lab PHT 434
The FDA: Basic Facts It takes 12 to 15 years to develop a single drug Only 1 in 10,000 potential medications makes it completely through the process Only.
Evidentiary vs Non-evidentiary Enabling Learning Objectives 1. Define evidentiary and non-evidentiary. 2. Select from a list the requirements for an alcohol.
QUALITY CONTROL IN THE IVF LAB.
Expectations for Facilities & cGMPs Biological Response Modifiers Advisory Committee Meeting October 9, 2003 Nicholas Obiri, Ph.D. CBER.
Internal environmental audit procedure Purpose: To ensure that the environmental management system is used and is effective Scope: The entire environmental.
Environmental Cleaning Tool Kit Funded through the AORN Foundation and supported by a grant from Ecolab Quality in Environmental Cleaning Module 6.
GTP Scenario # 5 September 17,2005. Scenario # 5 The CTL is hospital-based and manufactures 351 & 361 products. The CTL is hospital-based and manufactures.
Reporting Scenario # 5 September 18, Scenario # 5 Ms. Wright has malignant melanoma. Ms. Wright has malignant melanoma. Tumor obtained at resection.
Problem Management Scenario # 2 September 17,2005.
Reporting Scenario # 4 September 18, Scenario # 4 Mr Brando is entered on single- arm phase I/II tiral of allogeneic unrelated donor MSCs for the.
UnionPay Card Manufacturer Certification Introduction.
Quality Control significance in pharmaceutical industry
Clinical Trials.
Get Complete File From exam-dumps.html exam-dumps.html.
Drug Development Process Stages involved in Regulating Drugs
Wire Procurement and Wire Joint Production
Good Manufacturing Practices
C. 24-well whole blood (HIV+)
נמטוציטים משושנת ים Eli. S Lec. No.2.
FDA Guide To Aseptic Processing
GTP Scenario # 4 September 17,2005.
Pre-operative Assessment and Intra operative Nursing Role
Presentation on Good Manufacturing Practice
Lesson 5: BRITE Seminar: GMP II
Quality Systems in a Production Facility
Reporting Scenario # 3 September 18, 2005.
Lessons Learned from the Mistakes of Others
Section 4 – Safety in the Laboratory
From Cesium to X-Ray: A Cell Therapy Perspective
Environmental Cleaning Tool Kit
Manufacture of Sterile Medicinal Products: ‘Annex 1’ - DRAFT
Presentation transcript:

GTP Scenario # 2 September 17,2005

Scenario # 2 Dr. Good received IND approval for CD8 depletion of allogeneic PBMC for a Phase I/II clinical trial. Dr. Good received IND approval for CD8 depletion of allogeneic PBMC for a Phase I/II clinical trial.

Laboratory Information Cell Therapy Laboratory: Cell Therapy Laboratory: Unclassified facility. Unclassified facility. BSC cleaned with 10% bleach before use (1 product per BSC). BSC cleaned with 10% bleach before use (1 product per BSC). BSC is certified annually. BSC is certified annually. Depletion is performed in the general laboratory area (not within BSC). Depletion is performed in the general laboratory area (not within BSC). Product sampling is performed in the BSC. Product sampling is performed in the BSC. What level of EM and Cleaning is required? What level of EM and Cleaning is required?

What should be considered? Evaluate the conditions. Evaluate the conditions. The process is ‘functionally closed’. The process is ‘functionally closed’. The product is a 351 IND product. The product is a 351 IND product. The laboratory in which the depletion process occurs is an unclassified room. The laboratory in which the depletion process occurs is an unclassified room. Other processing (sampling, antibody addition) occurs in the BSC. Other processing (sampling, antibody addition) occurs in the BSC.

Product Monitoring Sterility: Pre & Post processing? Sterility: Pre & Post processing? Recommended Recommended Periodic audit review of sterility results? Periodic audit review of sterility results? Recommended Recommended

BSC Environmental Monitoring Settle plates during processing? Settle plates during processing? Recommend as part of process validation. Determine need based on data. Recommend as part of process validation. Determine need based on data. Surface sampling after cleaning? Surface sampling after cleaning? Perform as part of validation and as periodic check of cleaning procedure. Perform as part of validation and as periodic check of cleaning procedure. Airborne sampling during processing? Airborne sampling during processing? Not recommended. Not recommended.

Facility Monitoring Perform air particle counts during processing? Perform air particle counts during processing? Recommend monthly checks during laboratory ‘working hours’ (dynamic monitoring). Recommend monthly checks during laboratory ‘working hours’ (dynamic monitoring).

Personnel Monitoring Perform on day of processing after the staff completes the process? Perform on day of processing after the staff completes the process? Recommend performing during processing only if products begin to have positive sterility results. Recommend performing during processing only if products begin to have positive sterility results.

EM & PM Result Review How often? How often? Recommend monthly review. Recommend monthly review. Does this need to be done before product release? Does this need to be done before product release? Review cannot be part of product release; the product is infused immediately after processing (fresh). Review cannot be part of product release; the product is infused immediately after processing (fresh).

Cleaning BSC? BSC? Depletion Device? Depletion Device? Lab benchtops? Lab benchtops? Lab floors? Lab floors? Document Review? Document Review?

Cleaning Recommendations BSC BSC Cleaning with 10% bleach before & after use. Cleaning with 10% bleach before & after use. Unless post-processing cultures become positive (investigation outcome). Unless post-processing cultures become positive (investigation outcome).

Cleaning Recommendations Depletion Device & Benchtops: Depletion Device & Benchtops: Clean before & after use; Device using manufacturer’s instructions, Benchtop using 70% IPA. Clean before & after use; Device using manufacturer’s instructions, Benchtop using 70% IPA. Floors: Floors: Clean on a periodic basis. Clean on a periodic basis. Unless post-processing cultures become positive (investigation outcome). Unless post-processing cultures become positive (investigation outcome). Unless there is a spill. Unless there is a spill.

Cleaning Document Review How often? How often? Recommend periodic document review. Recommend periodic document review. Does this need to be done before product release? Does this need to be done before product release? Review should not be part of product release. Review should not be part of product release.

Variation # 1 Would you do anything differently if the blood had to be ficolled in conical tubes before depletion? Would you do anything differently if the blood had to be ficolled in conical tubes before depletion? Yes, refer to ‘open’ process recommendations. Yes, refer to ‘open’ process recommendations.

Variation # 2 Would you change anything if this were a Phase III study? Would you change anything if this were a Phase III study? No, unless required by the FDA. No, unless required by the FDA.